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Summary
To investigate the role of brain insulin action in the pathogenesis and treatment of diabetes, we asked whether neuronal in-
sulin signaling is required for glucose-lowering during insulin treatment of diabetes. Hypothalamic signaling via the insulin
receptor substrate-phosphatidylinositol 3-kinase (IRS-PI3K) pathway, a key intracellular mediator of insulin action, was re-
duced in rats with uncontrolled diabetes induced by streptozotocin (STZ-DM). Further, infusion of a PI3K inhibitor into the
third cerebral ventricle of STZ-DM rats prior to peripheral insulin injection attenuated insulin-induced glucose lowering by
w35%–40% in both acute and chronic insulin treatment paradigms. Conversely, increased PI3K signaling induced by hypo-
thalamic overexpression of either IRS-2 or protein kinase B (PKB, a key downstream mediator of PI3K action) enhanced the
glycemic response to insulin byw2-fold in STZ-DM rats. We conclude that hypothalamic insulin signaling via the IRS-PI3K
pathway is a key determinant of the response to insulin in the management of uncontrolled diabetes.Introduction
In addition to its effects in peripheral tissues, the pancreatic hor-
mone insulin communicates information regarding the suffi-
ciency of energy stores to brain areas involved in the control
of energy homeostasis and glucose metabolism (Flier, 2004;
Obici and Rossetti, 2003; Schwartz and Porte, 2005). Acting
through its receptor in hypothalamic areas such as the arcuate
nucleus (ARC) (Schwartz et al., 1992a), insulin promotes nega-
tive energy balance (by reducing food intake) (Woods et al.,
1979) and reduces blood-borne concentrations of nutrients
such as glucose (by inhibiting endogenous glucose production)
(Obici et al., 2002c). A physiological role for these actions of in-
sulin is suggested by the obese, insulin-resistant phenotype of
mice lacking neuronal insulin receptors (Bruning et al., 2000),
and by evidence that in rats, reduced hypothalamic insulin sig-
naling increases both food intake and hepatic glucose produc-
tion (Obici et al., 2002a). Similar effects are seen inmice in which
IRS-2, an intracellular mediator of insulin signaling, is deleted
from both hypothalamic neurons and pancreatic b cells using
Cre-loxP technology (Kubota et al., 2004; Lin et al., 2004). In ad-
dition, the ability of a physiological increase of plasma insulin
levels to suppress hepatic glucose production requires its action
in mediobasal hypothalamus in normal rats (Pocai et al., 2005a).
These findings raise the possibility that in individuals with diabe-
tes, the ability of insulin to normalize elevated blood glucose lev-
els depends in part on its action in the brain. Investigating this
hypothesis provides the central focus for the current work.
As in peripheral tissues, neuronal insulin action involves the in-
tracellular IRS-PI3K signal transduction pathway. Thus, hypo-
thalamic IRS-PI3K signaling increases following either intracere-CELL METABOLISM 3, 67–73, JANUARY 2006 ª2006 ELSEVIER INC.broventricular (icv) or systemic insulin administration (Niswender
et al., 2003), and the inhibitory effect of icv insulin on both food
intake (Niswender et al., 2003) and hepatic glucose production
(Obici et al., 2002b) can be blocked by icv pretreatment with a
PI3K inhibitor. We therefore sought to determine whether hypo-
thalamic PI3K signaling is reduced in rats with untreated insulin-
deficient diabetesmellitus induced by the b cell toxin, streptozo-
tocin (referred to here as ‘‘uncontrolled diabetes’’ or ‘‘STZ
diabetes’’) (Booth, 1972) and if so, whether hypothalamic signal-
ing via this is pathway plays an essential role in the glycemic
response to insulin.
Results
As previously reported (Havel et al., 2000; Qu et al., 2001), STZ
administration to male Sprague-Dawley rats induced marked
hyperglycemia (Figure 1A) and hypoinsulinemia (STZ-DM, 36 6
4 pmol/L versus Non-Diabetic, 231 6 21 pmol/L, p < 0.0001,
n = 8) that was associated with increased hypothalamic Npy
and Agrp (Figures 1B and 1D) and reduced pro-opiomelanocor-
tin (Pomc) mRNA levels (Figure 1D). The content of serine-
phosphorylated protein kinase B (PKB-PO4, a marker of PI3K
activity) in extracts of mediobasal hypothalamus was reduced
by 36% in STZ- compared to vehicle-treated rats as determined
by ELISA (Figure 1E), a finding confirmed by immunoblot analy-
sis (data not shown). Twenty minutes after central insulin admin-
istration (5 mU icv), hypothalamic serine-PKB-PO4 levels were
markedly increased in STZ-DM rats studied at both early (by
2.5-fold over vehicle on day 8; p < 0.001; n = 4–6) and later
time points (by 2.8-fold on day 21; p < 0.001; n = 5-6; Figure 1F)DOI 10.1016/j.cmet.2005.11.013 67
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rosine phosphorylation of threonine305 of PKB, and hypotha-
lamic content of threonine-phosphorylated PKB was increased
by insulin treatment in STZ-DM rats (Figure S1 in the Supple-
mental Data available with this article online). Signaling via the
Figure 1. Effects of STZ-DM on hypothalamic PI3K signaling and neuropeptide
gene expression
Eight days after sc injection of vehicle or STZ, rats were sacrificed for measure-
ment of (A) blood glucose levels, (B–D) hypothalamic neuropeptide gene expres-
sion, or (E) hypothalamic levels of phsophoSER473-PKB and total PKB levels by
ELISA. (F) Hypothalamic phsophoSER473-PKB levels were measured 20min after
vehicle or insulin administration (5 mU icv) to rats with STZ-DM. Data are mean 6
SEM, n = 6–8/group. *, p < 0.05; ***, p < 0.001 versus control.68IRS-PI3K pathway is therefore reduced in the mediobasal hypo-
thalamus of rats with STZ-DM, and this effect is rapidly reversed
with insulin treatment.
To determine whether increased hypothalamic IRS-PI3K sig-
naling is required for intact glucose lowering during insulin treat-
ment of diabetes, two consecutive pretreatment injections of the
PI3K inhibitor LY294002 (LY; 1 nmol icv, a dose that blocks the
anorexic response to icv insulin (Niswender et al., 2003)) or its ve-
hiclewereadministered (at212hrand21hr) to ratswithSTZ-DM
prior to a systemic insulin injection (2 U/kg ip). Compared to STZ-
DM rats receiving icv vehicle, icv pretreatmentwith LYattenuated
the glycemic effect of systemically-administered insulin by 35%
(Inverse AUCGlucose: 16324 6 4541 versus 25756 6 757 mg/dl/
120 min, p < 0.05, n = 7–11; Figures 2A and 2B). This effect can-
not be attributed to leakage of the PI3K inhibitor into the periph-
ery, since ip administration of the same LY dose did not alter in-
sulin’s glucose-lowering effect (Figures 2C and 2D).
To investigate whether hypothalamic IRS-PI3K signaling is a
determinant of insulin requirements during chronic insulin treat-
ment of diabetes, STZ-DM rats underwent sc implantation of an
osmotic minipump that delivered either LY (200 ng/0.50 ml/h) or
vehicle continuously into the third cerebral ventricle. Three days
later, daily treatment with either a long-acting insulin preparation
(insulin glargine, 7 mU/kg sc) or saline vehicle was commenced.
Whereas icv LY infusion had no effect on the hyperglycemia
induced by STZ in the absence of insulin treatment (Figure 2E),
the glycemic response to daily insulin treatment was attenuated
by 38% in animals receiving continuous icv infusion of LY
(Figure 2F). Hypothalamic insulin signaling via IRS-PI3K, there-
fore, appears to be necessary for effective glucose lowering
by insulin in the daily management of diabetes. Since the inhib-
itory action of LY is not 100% specific for PI3K, the possibility
remains that inhibition of other neuronal enzyme systems con-
tributed to this outcome. One way to address this issue is to de-
termine whether an increase of hypothalamic signaling via IRS-
PI3K induces an effect opposite to that of icv LY infusion in our
model.
To accomplish this, we directed adenovirus encoding either
IRS-2 (AdV-IRS2) or a reporter gene (AdV-lacZ or AdV-GFP) to
the ARC of STZ-DM rats using an established stereotaxic micro-
injection technique (Morton et al., 2005, 2003). Successful local-
ization of adenovirus expression to the area of the ARC (Fig-
ure 3A) and induction of IRS-2 expression in this brain area
was confirmed in a subset of animals (Figure 3B). Four days fol-
lowing AdV delivery, STZ was given to both groups and, as ex-
pected, blood glucose levels rose steadily. However, both the
onset of STZ-induced hyperglycemia and timing of peak blood
glucose values were delayed in rats receiving AdV-IRS2 com-
pared to AdV-lacZ (Figure 3C), despite no difference in either
food intake (Figure 3D) or body weight (Dbody weight for the
5-day period following STZ-treatment; AdV-IRS2, + 0.9 6 4.5
versus AdV-lacZ, –1.16 8.7 g, n = 5-8) between groups. Never-
theless, blood glucose levels in STZ-DM rats receiving Ad-IRS2
eventually rose to values comparable to those of animals treated
with AdV-lacZ.
To explain this outcome, we hypothesized that ARC-directed
IRS-2 gene therapy increased insulin sensitivity in peripheral tis-
sues and thereby slowed the rise of plasma glucose induced by
falling insulin levels. Once pronounced STZ-induced hypoinsuli-
nemia was established, however, we reasoned that the insulin-
sensitizing effect conferred by increased hypothalamic PI3KCELL METABOLISM : JANUARY 2006
Brain insulin action and diabetes treatmentFigure 2. Attenuation of the glycemic response to
insulin in STZ-DM rats following icv pretreatment
with a PI3K inhibitor
Eightdaysfollowing inductionofSTZ-DM, rats received
two consecutive icv injections of either LY294002 (LY)
or vehicle at 12 hr and 1 hr prior to being challenged
with insulin (2 U/kg ip).
A) Blood glucose was determined every 15–30 min
over 2 hr and (B) the inverse integrated area under
the curve (Inverse AUC glucose) was determined.
To control for leakage of LY into the bloodstream,
the response to insulin was measured (C and D) in
separate groups of STZ-DM rats that received an ip
injection of the same dose of LY or vehicle. Data rep-
resent the mean6 SEM, n = 7–11/group. *, p < 0.05;
**, p < 0.01; Ly versus Veh. (E and F) Effect of contin-
uous icv delivery of the PI3K inhibitor LY294002 on
the ability of daily administration of a long-acting in-
sulin analog, insulin glargine, to reducebloodglucose
levels in STZ-DM rats. Insulin/Veh treatment began
on day 0 (day 14, post STZ treatment). Data are
mean6SEM, n=7–9/group. *, p<0.05; **, Ly/Ins ver-
sus Veh/Ins.signaling would no longer be detectable. To test this hypothesis,
we measured the ability of systemic insulin to lower blood glu-
cose in STZ-DM rats after hypothalamic gene therapywith either
IRS-2 or control adenovirus. Because of difficulties inherent in
detecting a heightened glucose-lowering response to systemic
insulin treatment (2 U/kg ip) in animals with normal insulin sensi-
tivity, we chose to study rats with STZ-DM of sufficient duration
(18 days) to become insulin resistant due to chronic insulin de-
ficiency (Bevilacqua et al., 1985; Maegawa et al., 1986). As ex-
pected, the glucose-lowering effect of insulin in animals on
day 18 was reduced relative to rats with STZ-DM of shorter du-
ration (Figures 3E and 3F), compatible with the induction of insu-
lin resistance, and this response to insulin was increased >2-fold
by ARC-directed IRS-2 gene therapy compared to STZ-DM
rats receiving a control adenovirus (Figures 3G and 3H; Inverse
AUCGlucose: 12562 6 2301 versus 5625 6 1201 mg/dl/120 min.
p < 0.05, n = 5–8). Increased hypothalamic IRS-2 expression,CELL METABOLISM : JANUARY 2006therefore, strongly enhances the response of diabetic rats to
systemic insulin treatment of diabetes.
Because IRS-2 links the insulin receptor to multiple signal
transduction pathways (e.g., MAP kinase, in addition to PI3K),
we sought to provide an additional test of the hypothesis that in-
creased hypothalamic signaling via the IRS-PI3K pathway aug-
ments the glucose-lowering response to insulin in rats with un-
controlled diabetes. We therefore repeated the above study,
substituting an adenovirus expressing a constitutively active
mutant of PKB (AdV-CA) for AdV-IRS2. As predicted, we found
that the ability of systemic insulin to lower blood glucose in rats
with STZ-DM was augmented by nearly 2-fold by ARC directed
microinjection of AdV-CA relative to control adenovirus (AdV-
Luc) (Figures 3I and 3J). In a separate group of animals with
STZ-DM, we replicated the effect of ARC-directed gene therapy
with AdV-IRS2 to potentiate insulin-induced glucose lowering
byw2-fold (data not shown).69
S H O R T A R T I C L EFigure 3. Effect of duration of STZ-DM on glucose
lowering by insulin and hypothalamic adenoviral
gene therapy on food intake and blood glucose
levels in STZ-DM rats
Expression of GFP (A) and IRS-2 (B) in mediobasal
hypothalamus following ARC-directed adenovirus
microinjection. (C) Time course of changes in blood
glucose or 5 day cumulative food intake (D) in STZ-
DM rats receiving ARC-directed IRS-2 gene therapy
or a control adenovirus (AdV-lacZ). (EandF) Glucose-
lowering effect of insulin (2 U/kg ip)measured 8 d and
18 d following STZ administration to male Sprague
Dawley rats. (G and H) Glucose-lowering effect of in-
sulin (2 U/kg ip) measured 18 d following STZ admin-
istration, in STZ-DM rats receiving adenoviral gene
therapy with AdV-IRS2 or reporter virus (AdV-lacZ).
(I and J) A similar enhancement of insulin’s ability
to lower blood glucose was observed in STZ-DM
rats receiving gene therapy with AdV-CA compared
to reporter virus (AdV- Luc). Data represent the
mean 6 SEM, n = 5–9/group. *, p < 0.05; **, p <
0.01; ***, p < 0.001 versus Con.70 CELL METABOLISM : JANUARY 2006
Brain insulin action and diabetes treatmentDiscussion
Until recently, the effects of insulin on glucose metabolism were
thought to be mediated solely by its actions on peripheral tis-
sues. However, mounting evidence in nondiabetic animal mod-
els has challenged this concept, revealing an important role for
neuronal insulin action in glucose homeostasis. For example,
the effect of third ventricular insulin administration to increase
the ability of circulating insulin to inhibit hepatic glucose produc-
tion in rats is well documented (Obici et al., 2002b), as is evi-
dence that reduced hypothalamic insulin action causes hepatic
insulin resistance (Obici et al., 2002a, 2002b). Additional support
stems from studies in which insulin receptors were restored se-
lectively to the brain, liver and pancreas of mice that otherwise
lack this receptor using a transgenic approach (Okamoto
et al., 2004). Collectively, these findings raise the possibility
that treatment of uncontrolled diabetes depends upon intact
neuronal insulin signaling and, therefore, that brain insulin action
is a determinant of insulin requirements among individuals with
diabetes.
Our current studies support both of these predictions. We
found that IRS-PI3K signaling is reduced in the mediobasal hy-
pothalamus of rats with STZ-DM, that this reduction is readily re-
versed by insulin treatment, and that infusion of an inhibitor of
PI3K signaling into the 3rd cerebral ventricle attenuates the gly-
cemic response of diabetic animals to systemic insulin treat-
ment. Thus, hypothalamic insulin signaling is required for an
intact glycemic response to insulin treatment of diabetes. Con-
versely, blood glucose lowering by systemic insulin treatment
was greatly enhanced by increasing signaling upstream (IRS-2)
of PI3K in the mediobasal hypothalamus of animals with STZ-
DM. Surprisingly, we did not detect an increase of insulin-
induced serine-phosphorylated PKB content in diabetic rat hy-
pothalamus following Ad-IRS2 gene therapy (data not shown).
We therefore hypothesized that our assay of mediobasal hypo-
thalamic extracts lacks the sensitivity required to detect
changes of PI3K signaling that occur in the relatively small pro-
portion of cells transduced by adenovirus in vivo. To further in-
vestigate whether increased IRS-PI3K signaling mediates the
response to a localized increase in hypothalamic expression
of IRS2, we injected adenovirus encoding a constitutively active
PKB mutant into the area of the ARC of STZ-DM rats. The aug-
mentation of insulin-induced glucose lowering resulting from
this intervention mimicked that seen with hypothalamic IRS-2
gene therapy. This finding suggests both that the response to
Ad-IRS-2 involves signal transduction via PKB and that in-
creasedhypothalamicsignalingeitherupstream (IRS-2)ordown-
stream (PKB) of PI3K is sufficient to enhance insulin-induced
glucose lowering in diabetic rats. These findings collectively im-
plicate hypothalamic insulin signaling via the IRS-PI3K pathway
as a key determinant of the glycemic response to insulin in ani-
malswith uncontrolled diabetes. The sensitivity of the brain to in-
sulin may therefore represent a previously unrecognized deter-
minant of insulin requirements in patients with diabetes.
Among neuronal subsets with the potential to mediate the
central action of insulin on glucose metabolism, NPY/Agrp neu-
rons in the ARC are of particular interest. In addition to exerting
potent orexigenic effects, central administration of NPY sharply
decreases hepatic insulin sensitivity (Marks and Waite, 1997;
van den Hoek et al., 2004) whereas both hyperphagia and hy-
perglycemia induced by STZ-DM are attenuated in mice withCELL METABOLISM : JANUARY 2006genetic NPY deficiency (Sindelar et al., 2002). Thus, both behav-
ioral and glycemic manifestations of uncontrolled diabetes ap-
pear to depend in part on NPY signaling. Since insulin inhibits
hypothalamic NPY gene expression (Schwartz et al., 1992b), it
is temping to speculate that the effect of insulin deficiency to ac-
tivate hypothalamic NPY neurons contributes to hyperglycemia,
as well as to hyperphagia, characteristic of uncontrolled diabe-
tes. According to this model, effective insulin treatment of un-
controlled diabetes is predicted to depend upon inhibition of
these key hypothalamic neurons, and additional studies are
warranted to investigate this hypothesis.
While the efferent mechanism coupling hypothalamic insulin
signaling to changes of peripheral glucose metabolism remains
to be fully elucidated, recent findings suggest that activation
of KATP channels in mediobasal hypothalamic neurons is re-
quired for this effect (Pocai et al., 2005a). In this regard, the hy-
pothalamic response to insulin closely resembles the effect of
increased hypothalamic long-chain fatty acyl Co-A signaling to
reduce hepatic glucose production (Pocai et al., 2005b). This re-
sponse to both insulin and fatty acyl Co-A involves communica-
tion between hypothalamic neurons and hindbrain areas con-
trolling parasympathetic outflow to the liver via the vagus nerve.
In summary, we report that insulin signaling via the hypotha-
lamic IRS-PI3K pathway is a determinant of the glycemic re-
sponse of animals with uncontrolled diabetes to systemic insulin
treatment. Therapeutic strategies that target neuronal insulin
signal transduction molecules may therefore prove beneficial
in the management of diabetes in humans.
Experimental procedures
Animals
All experimental protocols were approved by the University of Washington
Institutional Animal Care and Use Committee. Adult male Sprague Dawley
rats (Charles River, Wilmington, MA) weighing 250–350 g were individually
housed, fed a standard commercial diet (LabDiet, Richmond, IN) and pro-
vided with water ad libitum. Animals were maintained on a 12h/12h light/
dark cycle with lights on at 0600h. Uncontrolled diabetes was induced with
two consecutive daily subcutaneous (sc) doses of freshly prepared strepto-
zotocin (40 mg/kg dissolved in ice-cold 0.1 M sodium citrate, pH 4.5), and
blood glucose levels (from tail capillary samples), body weight and food in-
takeweremeasured daily. Cannulation of the third cerebral ventricle was per-
formed as previously described (Schwartz et al., 1992b). After a one-week re-
covery period, correct cannula placement was assessed by measuring the
drinking response to icv injection of angiotensin II (AGII; 10 mg; American
peptide, Sunnyvale, CA) diluted saline (injection volume: 1 ml) (Schwartz
et al., 1992b).
Study protocols: Effect of icv LY294002 on the response to insulin
Acute study
To investigate whether hypothalamic PI3K signaling is required for the glyce-
mic response to insulin, two groups of rats outfitted with an indwelling 3rd
venricular cannula were studied 1 wk after STZ administration. Each animal
received an icv injection of either LY294002 (1 nmol) or its vehicle both 12-
and 1 hr prior to a systemic insulin challenge. The acute glycemic response
to insulin was determined by measuring blood glucose levels at 15–30 min
intervals for 2 hr after the administration of insulin (2 U/kg ip). While this ap-
proach to themeasurement of insulin action can be confounded by induction
of counter-regulatory responses in the event of hypoglycemia, the current
studies were limited to hyperglycemic STZ-diabetic rats that did not develop
hypoglycemia during insulin treatment.
Chronic study
Oneweek after STZ administration to two groups of rats (n = 14-18/group), an
osmotic minipump (Alzet minpumps, DURECT Corporation, Cupertino, CA)
that delivered either LY294002 (200 ng/0.5 ml/h) or vehicle was implanted
subcutaneously and connected to an indwelling 3rd ventricular cannula. After71
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mals in each group received saline control sc, while the other half received
the long acting insulin preparation, insulin glargine (Lantus, Aventis Pharma-
ceuticals, Inc., Germany; 7 mU/kg sc). Blood glucose, food intake and body
weight were measured daily for 3 d.
Response to adenoviral gene therapy
Adenoviruses (AdV) expressing either a reporter gene (lacZ, GFP or Lucifer-
ase), IRS-2, or a constitutively active PKB mutant (AdV-CA) were generated
and purified as previously described (Lingohr et al., 2002). Rats were placed
in a stereotaxic frame (Cartesian Research, Inc., Sandy, OR) under isoflurane
anesthesia. The ARC was targeted bilaterally by performing two unilateral in-
jections using aWPI UMPII Pump Adaptor (WPI, Sarasota, FL) and a 28-g sy-
ringe system (Hamilton Syringes, Reno, NV) directed to stereotaxic coordi-
nates 2.8 mm posterior to bregma, 6 0.30 mm lateral to the midline, and
10.5 mm below the surface of the skull (Morton et al., 2005; Morton et al.,
2003). Adenovirus (2 3 1012 pfu/ml) was infused at a rate of 100 nl/min for
5 min (500 nl/injection site). Both the anatomical distribution of and success-
ful expression of protein products of the encoded genes have been exten-
sively characterized and adenoviral delivery of reporter genes to the area
of the ARC does not influence daily food intake or body weight in normal
rats (Morton et al., 2003). Four days following ARC-directed gene therapy,
STZ was administered and blood glucose, food intake and body weight
were measured daily. On day 18 following the induction of diabetes, the
acute glycemic response to an insulin challenge (2 U/kg ip) was determined.
Effect of STZ-DM on hypothalamic gene expression
and PI3K signaling
Eight days following STZ injection, animals (n = 8–16/group) were sacrificed
at 0900–1000 by decapitation and trunk blood was collected for determina-
tion of hormone levels. A wedge of mediobasal hypothalamus (defined cau-
dally by the mamillary bodies; rostrally by the optic chiasm; laterally by the
optic tract; and superiorly by the apex of the hypothalamic third ventricle)
was rapidly dissected and frozen for subsequent biochemical analysis or
mRNA determination as previously described (Morton et al., 2003). In a sub-
set of these studies, icv saline or insulin (5 mU in 2 ml of saline) was adminis-
tered into the third ventricle on either day 8 or 21 following the induction of
STZ-DM. Rats were fasted for 6 hr prior to icv injection and were sacrificed
20 min later for removal of mediobasal hypothalamus and trunk blood as
above.
Biochemical analysis
Hypothalamic samples were lysed, homogenized and clarified, and protein
content determined. Thirty mg of total lysates were resolved by 10% SDS-
PAGE and immunoblotted with antibodies specific for the phosphorylated
forms of PKB (Ser473 or Thr308) (Cell signaling Technology, Beverly, MA); de-
tection was by enhanced cheimiluminescence (Pierce Biotechnology, Rock-
ford, IL) and film exposure. Total and phosphorylated levels of PKB (Ser473)
were also determined with a commercially available ELISA (Biosource Inter-
national, Camarillo, CA).
mRNA quantitation
RNA from hypothalamic tissue was isolated and underwent RT-PCR quanti-
fication as previously described (Morton et al., 2003). Primers were designed
to span an exon/intron boundary were optimized for mRNA encoding Npy,
Agrp, Pomc, irs-2 and Gapdh. Primer sequences are listed: NPY: fwd 50-ac
caggcagagatatggcaaga-30; rev 50-ggacattttctgtgctttctctcatta-30; Agrp: fwd
50-agggcatcagaaggcctgaccagg-30; rev 50-cattgaagaagcggcagtagcacgt-30;
POMC: fwd 50-cgctcctactctatggagcactt-30; rev 50-gtcggtagactcttcccagcat-
30; IRS-2: fwd50-tcaccccagtgtccccat-30; rev-50tgctgttgccttcactgctt-30;GAPDH:
fwd 50-aacgaccccttcattgac-30; rev 50-tccacgacatactcagcac-30.
Blood and plasma assays
Glucose levels were determined using a hand-held glucometer (Accu-Check,
Roche, Diagnostics, IN) on blood obtained from tail capillary samples.
Plasma immunoreactive insulin levels were determined by ELISA (Crystal
Chem, Inc., Chicago, IL).72Statistical analyses
Data are presented as mean6 SEM. For multiple group comparisons, statis-
tical significance was determined by one-way ANOVA using a Newman-
Keuls post-hoc test to assess differences between groups. For two-group
comparisons, an unpaired, two-tailed, Student’s t test was employed. A
p value < 0.05 was considered statistically significant.
Supplemental data
Supplemental Data include one figure and can be found with this article on-
line at http://www.cellmetabolism.org/cgi/content/full/3/1/67/DC1/.
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